Nifty
Sensex
:
:
10397.45
33844.86
37.05 (0.36%)
141.27 (0.42%)

Pharmaceuticals & Drugs

Rating :
34/99

BSE: 500124 | NSE: DRREDDY

2165.90
2.25 (0.10%)
21-Feb-2018 | 3:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 2180.20
  • 2202.00
  • 2140.75
  • 2163.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 498005
  • 10786.29
  • 2948.80
  • 1901.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 35,868.67
  • 35.43
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 40,400.67
  • 0.93%
  • 2.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.77%
  • 3.65%
  • 8.65%
  • FII
  • DII
  • Others
  • 0.24%
  • 13.19%
  • 47.50%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Net Sales
3,834.10
3,723.20
2.98%
3,559.80
3,616.30
-1.56%
3,333.20
3,222.50
3.44%
3,611.90
3,756.20
-3.84%
Expenses
3,041.40
2,858.70
6.39%
2,890.40
2,989.30
-3.31%
3,010.00
2,832.30
6.27%
3,021.40
3,279.70
-7.88%
EBITDA
792.70
864.50
-8.31%
669.40
627.00
6.76%
323.20
390.20
-17.17%
590.50
476.50
23.92%
EBIDTM
20.68%
23.22%
18.80%
17.34%
9.70%
12.11%
16.35%
12.69%
Other Income
43.00
40.30
6.70%
31.60
43.80
-27.85%
38.00
67.00
-43.28%
20.50
30.70
-33.22%
Interest
17.20
16.40
4.88%
22.30
12.60
76.98%
21.50
14.80
45.27%
19.60
264.60
-92.59%
Depreciation
271.50
266.50
1.88%
270.20
262.20
3.05%
259.20
243.60
6.40%
254.30
0.00
0.00
PBT
547.00
621.90
-12.04%
408.50
396.00
3.16%
80.50
198.80
-59.51%
337.10
242.60
38.95%
Tax
252.80
138.50
82.53%
112.30
95.60
17.47%
23.70
52.60
-54.94%
9.70
173.90
-94.42%
PAT
294.20
483.40
-39.14%
296.20
300.40
-1.40%
56.80
146.20
-61.15%
327.40
68.70
376.56%
PATM
7.67%
12.98%
8.32%
8.31%
1.70%
4.54%
9.06%
1.83%
EPS
18.26
29.69
-38.50%
18.42
18.63
-1.13%
4.02
9.27
-56.63%
20.36
4.37
365.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,339.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
4,991.80
Net Sales Growth
0.15%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
38.24%
 
Cost Of Goods Sold
4,038.00
3,444.90
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
1,601.20
Gross Profit
10,301.00
10,751.20
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
3,390.60
GP Margin
71.84%
75.73%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
67.92%
Total Expenditure
11,963.20
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
4,155.10
Power & Fuel Cost
-
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
97.60
% Of Sales
-
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
1.96%
Employee Cost
-
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
731.00
% Of Sales
-
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
14.64%
Manufacturing Exp.
-
2,138.20
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
768.40
% Of Sales
-
15.06%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
15.39%
General & Admin Exp.
-
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
395.80
% Of Sales
-
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
7.93%
Selling & Distn. Exp.
-
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
523.30
% Of Sales
-
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
10.48%
Miscellaneous Exp.
-
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
183.60
523.30
% Of Sales
-
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
0.76%
EBITDA
2,375.80
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
836.70
EBITDA Margin
16.57%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
16.76%
Other Income
133.10
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
214.10
Interest
80.60
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
102.20
Depreciation
1,055.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
401.90
PBT
1,373.10
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
546.70
Tax
398.50
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
107.70
Tax Rate
29.02%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
19.70%
PAT
974.60
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.80
PAT before Minority Interest
974.60
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.80
PAT Margin
6.80%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
8.81%
PAT Growth
-2.41%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
-308.53%
 
Unadjusted EPS
61.06
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48
26.07

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
4,496.90
Share Capital
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
84.10
Total Reserves
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
4,377.60
Non-Current Liabilities
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
2,049.00
Secured Loans
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
64.20
Unsecured Loans
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
1,904.20
Long Term Provisions
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
0.00
Current Liabilities
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
1,150.80
Trade Payables
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
1,027.50
Other Current Liabilities
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
5.80
Short Term Borrowings
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
0.00
Short Term Provisions
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
117.50
Total Liabilities
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70
Net Block
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
3,912.50
Gross Block
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
5,487.80
Accumulated Depreciation
8,961.40
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
1,575.30
Non Current Assets
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
4,312.20
Capital Work in Progress
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
268.40
Non Current Investment
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
131.30
Long Term Loans & Adv.
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
0.00
Other Non Current Assets
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
0.00
Current Assets
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
3,384.50
Current Investments
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
350.80
Inventories
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
1,101.90
Sundry Debtors
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
652.20
Cash & Bank
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
744.70
Other Current Assets
1,218.70
393.10
226.20
170.40
961.90
705.80
879.60
660.90
551.90
534.90
Short Term Loans & Adv.
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
532.10
Net Current Assets
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
2,233.70
Total Assets
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
512.80
PBT
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
545.00
Adjustment
1,692.70
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
523.40
Changes in Working Capital
-525.00
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
-402.40
Cash after chg. in Working capital
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
666.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
-153.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
-810.40
Net Fixed Assets
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
-424.90
Net Investments
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
-1,100.39
Others
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
714.89
Cash from Financing Activity
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
-775.40
Net Cash Inflow / Outflow
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
-1,073.00
Opening Cash & Equivalents
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
1,861.00
Closing Cash & Equivalent
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30
744.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
265.26
ROA
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
5.70%
ROE
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
10.41%
ROCE
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
10.02%
Fixed Asset Turnover
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
0.99
Receivable days
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
51.82
Inventory Days
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
66.85
Payable days
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
85.15
Cash Conversion Cycle
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
33.52
Total Debt/Equity
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
0.44
Interest Cover
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07
6.35

News Update:


  • Dr. Reddy’s recalls over 80,000 bottles of Atorvastatin Calcium Tablets from US market
    9th Feb 2018, 08:44 AM

    Atorvastatin is a drug that blocks the production of cholesterol and reduces its level in the blood

    Read More
  • Dr. Reddy’s launches Tetrabenazine Tablets in US market
    2nd Feb 2018, 11:40 AM

    The company’s Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112

    Read More
  • Dr. Reddys Lab - Quarterly Results
    25th Jan 2018, 11:55 AM

    Read More
  • Dr. Reddy’s recalls single lot of Docetaxel injection vials from US
    18th Jan 2018, 09:02 AM

    The company has recalled the drug on account of defective container

    Read More
  • Dr. Reddy’s launches Melphalan Hydrochloride for Injection in US Market
    26th Dec 2017, 14:40 PM

    The Alkeran brand and generic had U.S. sales of around $107 million MAT for the most recent twelve months ending in October-2017

    Read More
  • Dr. Reddy’s arm reaches settlement with US Government
    19th Dec 2017, 08:45 AM

    The settlement is in a case that is more than six years old, involving packaging for five blister-packed prescription products

    Read More
  • Dr. Reddy’s receives EIR from USFDA for Hyderabad facility
    12th Dec 2017, 09:22 AM

    The company for received EIR for its Formulations Manufacturing Plant - 3 as closure of audit

    Read More
  • Dr. Reddy’s receives EIR from USFDA for Telangana facility
    2nd Dec 2017, 09:47 AM

    The company has received EIR for its Custom Pharmaceutical Services facility, Technology Development Centre at Miyapur, Hyderabad

    Read More
  • Dr. Reddy’s gets first-cycle NDA approval for Impoyz Cream
    1st Dec 2017, 10:49 AM

    This approval is another example of the deep and broad capabilities within the Proprietary Products business unit at Dr. Reddy's

    Read More
  • Dr. Reddy’s faces securities class action lawsuit in US
    30th Nov 2017, 10:16 AM

    The lawsuit filed at the District Court for New Jersey seeks damages to compensate the class of investors

    Read More
  • Dr. Reddy’s receives EIR from USFDA for Vishakhapatnam facility
    21st Nov 2017, 10:27 AM

    The company is planning to request a re-inspection in 2018 after further discussion on scheduling with USFDA

    Read More
  • Dr. Reddy’s launches Clofarabine Injection in US market
    14th Nov 2017, 13:44 PM

    Dr. Reddy’s Laboratories’ Clofarabine Injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL)

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.